{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:36:48Z","timestamp":1773265008864,"version":"3.50.1"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1677","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Eflapegrastim-xnst (Rolvedon [Spectrum]; previously called Rolontis), a granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG4, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia.<\/jats:p>","DOI":"10.58347\/tml.2023.1677b","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T19:13:46Z","timestamp":1683832426000},"page":"83-84","source":"Crossref","is-referenced-by-count":2,"title":["Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,5,29]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T19:13:46Z","timestamp":1683832426000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1677b"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":0,"journal-issue":{"issue":"1677","published-online":{"date-parts":[[2023,5,29]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1677b","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]}}}